Literature DB >> 8823372

Lymphocyte-mediated alopecia in C57BL/6 mice following successful immunotherapy for melanoma.

J C Becker1, N Varki, E B Bröcker, R A Reisfeld.   

Abstract

Successful immunotherapy of established B16 melanoma metastases in C57BL/6 mice can be achieved by antibody-targeted interleukin-2 administration. This therapeutic effect is accompanied in approximately 20% of the animals by induction of a population of lymphocytes that migrates to and substantially disrupts the cytoarchitecture of the skin, which results in progressive alopecia. The histologic changes associated with the hair loss, i.e., peri-, and intrafollicular inflammatory infiltrates consisting of both activated CD4+ and CD8+ T cells, as well as expression of major histocompatibility complex class I antigens on subinfundibular follicle epithelium, are similar to those observed in human alopecia areata. Furthermore, the alopecic phenotype can be transmitted horizontally by passive transfer of lymphocytes from treated animals to naïve mice. Since lymphocytes from treated animals either lacking or displaying signs of alopecia are able to transmit these phenotypic changes to a similar percentage of naïve animals, the initiation of alopecia seems to be dependent on the coincidence of at least two different events: the presence of specific lymphocyte populations as well as specific features of the skin disclosing a target for these cells.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8823372     DOI: 10.1111/1523-1747.ep12584237

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  7 in total

Review 1.  Hypopigmentary skin disorders: current treatment options and future directions.

Authors:  Anke Hartmann; Eva-B Bröcker; Jürgen C Becker
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 2.  The role of lymphocytes in the development and treatment of alopecia areata.

Authors:  Hongwei Guo; Yabin Cheng; Jerry Shapiro; Kevin McElwee
Journal:  Expert Rev Clin Immunol       Date:  2015-09-07       Impact factor: 4.473

3.  A mouse model of clonal CD8+ T lymphocyte-mediated alopecia areata progressing to alopecia universalis.

Authors:  Rajshekhar Alli; Phuong Nguyen; Kelli Boyd; John P Sundberg; Terrence L Geiger
Journal:  J Immunol       Date:  2011-11-23       Impact factor: 5.422

4.  Activation of preexisting T cell clones by targeted interleukin 2 therapy.

Authors:  P T Straten; P Guldberg; T Seremet; R A Reisfeld; J Zeuthen; J C Becker
Journal:  Proc Natl Acad Sci U S A       Date:  1998-07-21       Impact factor: 11.205

Review 5.  What causes alopecia areata?

Authors:  K J McElwee; A Gilhar; D J Tobin; Y Ramot; J P Sundberg; M Nakamura; M Bertolini; S Inui; Y Tokura; L E King; B Duque-Estrada; A Tosti; A Keren; S Itami; Y Shoenfeld; A Zlotogorski; R Paus
Journal:  Exp Dermatol       Date:  2013-09       Impact factor: 3.960

6.  A mouse model of vitiligo with focused epidermal depigmentation requires IFN-γ for autoreactive CD8⁺ T-cell accumulation in the skin.

Authors:  John E Harris; Tajie H Harris; Wolfgang Weninger; E John Wherry; Christopher A Hunter; Laurence A Turka
Journal:  J Invest Dermatol       Date:  2012-02-02       Impact factor: 8.551

Review 7.  Autoantigen Discovery in the Hair Loss Disorder, Alopecia Areata: Implication of Post-Translational Modifications.

Authors:  Shahnawaz D Jadeja; Desmond J Tobin
Journal:  Front Immunol       Date:  2022-06-03       Impact factor: 8.786

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.